Integrating Immunotherapy Into the Treatment of Hepatocellular Carcinoma: A Multidisciplinary Perspective

Review the mechanism of action for immune checkpoint inhibitors, the rationale and data supporting their use in HCC, and key issues and controversies around moving this new class of agents into the clinic from the live satellite symposium at AASLD 2016.
Ghassan K. Abou-Alfa, MD, MBA
Osama E. Rahma, MD
Tamar Taddei, MD
Andrew X. Zhu, MD, PhD, FACP
Released: December 5, 2016

Information on this Educational Activity

Faculty

Ghassan K. Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Ghassan K. Abou-Alfa, MD, has disclosed that he and/or his spouse have received consulting fees from Aduro, Agios, Array, Aslan, Astellas Pharma US, Bayer, Blueprint Medicines, Boston Scientific, Bristol-Myers Squibb, Celgene, CASI, Celsion, Delcath, Eisai, EMD Serono, Gilead Sciences, Halozyme, IntegraGen, Ipsen, Janssen, Merck, Merrimack, Momenta, New B Innovation, NewLink Genetics, Onxeo, Opsona, Pfizer, Roche, sanofi-aventis, Servier, Silenseed, Sillajen, Sirtex, Vaxxim, Vicus, and Westhaven and funds for research support from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, CASI, Celgene, Chugai, Exelixis, Genentech, Incyte, Lilly, MabVax, MedImmune, Momenta, Myriad Genetics, OncoMed, Polaris, Roche, and Vicus.
Osama E. Rahma, MD

Member of the Faculty of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Osama E. Rahma, MD, has disclosed that he has received research funding from Merck.
Tamar Taddei, MD

Associate Professor of Medicine
Division of Digestive Diseases
Department of Medicine
Yale University
Director, Liver Cancer Programs
Smilow Cancer Hospital
Yale-New Haven Hospital
New Haven, Connecticut

Tamar Taddei, MD, has disclosed that she has received consulting fees and funds for research support from Bayer.
Andrew X. Zhu, MD, PhD, FACP

Professor of Medicine
Harvard Medical School
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Andrew X. Zhu, MD, PhD, FACP, has disclosed that he has received consulting fees from Bristol Myers-Squibb, Eisai, Merck, Nimbus, Novartis, Onkaido, and sanofi-aventis and funds for research support from Lilly.

Program Medium

This program has been made available online.

Related Content

Download this slideset to review the latest data on best practices for the care of patients with HCC across the disease spectrum and to address specific issues unique to treating veterans.

Released: September 19, 2017

In this downloadable slideset, Tim F. Greten, MD, reviews the rationale for immunotherapy in the treatment of HCC and promising data on the use of immune checkpoint inhibitors.

Released: June 7, 2017

In this downloadable slideset, Peter R. Galle, MD, PhD, reviews the key data on emerging targeted therapies and novel targets for HCC.

Released: June 7, 2017

In this downloadable slideset, Tanios Bekaii-Saab, MD, FACP, reviews the key data on approved systemic therapies and optimal management of HCC.

Released: June 7, 2017

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?